Showing results (111-120 of 204) with videos related to
Sort By:
Pageof 21
Exploration of Targeted Anti-Tumor Therapy|July 17, 2023
Real world outcomes in patients with neuroendocrine tumor receiving peptide receptor radionucleotide therapyStijn Hentzen, Kathan Mehta, Raed Moh'd Taiseer Al-Rajabi, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 9, 2011
Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancerDaniel G Haller, Josep Tabernero, Jean Maroun, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 2008
Oxaliplatin plus irinotecan compared with irinotecan alone as second-line treatment after single-agent fluoropyrimidine therapy for metastatic colorectal carcinomaDaniel G Haller, Mace L Rothenberg, Alfred O Wong, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 30, 2003
Safety and toxicity analysis of oxaliplatin combined with fluorouracil or as a single agent in patients with previously treated advanced colorectal cancerRamesh K Ramanathan, Jeffery W Clark, Nancy E Kemeny, et al.Clinical Colorectal Cancer|January 27, 2010
Current Opinion on Optimal Treatment Choices in First-line Therapy for Advanced or Metastatic Colorectal Cancer: Report From the Adelaide Colorectal Tumour Group Meeting; Stockholm, Sweden; September 2008Timothy J Price, Niall C Tebbutt, Christos S Karapetis, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 2, 2015
Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer: Final Results of the NO16968 Randomized Controlled Phase III TrialHans-Joachim Schmoll, Josep Tabernero, Jean Maroun, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 11, 2002
Phase I and pharmacokinetic trial of the proapoptotic sulindac analog CP-461 in patients with advanced cancerWeijing Sun, James P Stevenson, James M Gallo, et al.Cancer|December 19, 2018
A phase 2 trial of regorafenib as a single agent in patients with chemotherapy-refractory, advanced, and metastatic biliary tract adenocarcinomaWeijing Sun, Anuj Patel, Daniel Normolle, et al.The Lancet. Oncology|December 3, 2014
Effect of adjuvant capecitabine or fluorouracil, with or without oxaliplatin, on survival outcomes in stage III colon cancer and the effect of oxaliplatin on post-relapse survival: a pooled analysis of individual patient data from four randomised controlled trialsHans-Joachim Schmoll, Chris Twelves, Weijing Sun, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 10, 2008
Survival following recurrence in stage II and III colon cancer: findings from the ACCENT data setMichael J O'Connell, Megan E Campbell, Richard M Goldberg, et al.Pageof 21